Company: PRME
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038619
Chunk: 37

Company: Prime Medicine, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
(2,053)(5,672)Net cash used in operating activities(90,269)(113,198)Cash flows used in investing activities:Maturities of investments14,250 110,000 Purchases of investments(55,227)(135,912)Purchases of property and equipment(3,994)(4,226)Net cash used in investing activities(44,971)(30,138)Cash flows provided by financing activities:Proceeds from research and development funding liability6,000 6,000 Proceeds from follow-on offering, net of issuance costs— 132,055 Proceeds from issuance of pre-funded warrants, net of issuance costs— 18,800 Proceeds from ESPP offerings197 436 Net proceeds from stock option exercises— 71 Net cash provided by financing activities6,197 157,362 Net change in cash, cash equivalents, and restricted cash(129,043)14,026 Cash, cash equivalents, and restricted cash at beginning of period196,538 55,070 Cash, cash equivalents, and restricted cash at end of period$67,495 $69,096 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

9

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months EndedJune 30,(in thousands)20252024Reconciliation of cash, cash equivalents and restricted cash:Cash, cash equivalents, and restricted cash at end of period$67,495 $69,096 Less: restricted cash13,691 13,496 Total cash, and cash equivalents$53,804 $55,600 Supplemental cash flow information:Right-of-use assets obtained in exchange for new operating lease liabilities$83,757 $44,935 Decrease in right-of-use assets due to lease termination$3,120 $— Supplemental disclosure of non-cash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued expenses$148 $355 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

10

PRIME MEDICINE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.Nature of the Business and Basis of Presentation

Prime Medicine, Inc., together with its consolidated subsidiary (the